INVESTMENT

Supply chain, meet private equity

Private equity has reshaped dentistry for the last decade and a half, typically by rolling up dental practices into DSOs. But recently, the big bets haven't focused on small practices or niche operators. Instead, PE investors have turned their attention and capital to the dental industry's supply-side giants: suppliers and manufacturers like Henry Schein, Patterson, and ZimVie. 

But this isn’t your standard roll-up play. PE is aiming to shake up major established companies on the theory that they may have become complacent, undervalued, and yet totally worth some extra TLC. Let’s jump in to see why investors are putting their capital here, what it means for DSOs, and if the bets will pay off. 

What happened: Several major dental suppliers have attracted substantial private equity investment over the last year:

• Henry Schein & KKR (2025): KKR invested $250 million in Henry Schein, securing roughly 12 percent ownership and two board seats. Rather than rolling up smaller entities, KKR aims to streamline Schein's global operations and sharpen strategic focus.
  

• Patterson Companies & Patient Square Capital: Patterson was acquired by Patient Square Capital in a $4.1 billion transaction completed in April 2025. The company, previously public, is now private and will use this opportunity to realign strategically and operationally.
  

• ZimVie & ArchiMed: Dental implant specialist ZimVie agreed to be acquired by ArchiMed for $730 million, nearly double its previous valuation. ArchiMed sees ZimVie as undervalued and will focus on high-margin, growth-oriented dental implant products.
  

• HuFriedyGroup & Peak Rock Capital (2024): Steris Corp carved out its dental instruments division, HuFriedyGroup, selling it to Peak Rock Capital for $787.5 million. Peak Rock intends to build HuFriedyGroup as a standalone platform, optimizing products and operations.

Reshaping giants: Private equity sees major dental suppliers as ripe for strategic recalibration rather than simple consolidation like seen in clinic rollups:

• Operational bloat: The perception was that some of these dental giants had become bureaucratic and slow to innovate. Investors see opportunities to streamline operations and shed underperforming segments.
  

• Undervalued assets: Companies like ZimVie are seen as undervalued, despite holding strong fundamentals, by some analysts. PE believes focused leadership and capital can unlock untapped value.
  

• Improved profitability: PE firms are targeting operational efficiencies, technology integration, and reduced overhead to drive margin expansion at major dental players.
  

Implications for DSOs:  The restructuring of key suppliers will directly affect DSOs:

• Service and technology upgrades: PE-backed suppliers may improve efficiency, offer better technology integration, and enhance service levels. DSOs could benefit from streamlined procurement and advanced supplier capabilities.
  

• Pricing pressures: Fewer, more powerful suppliers could reduce the negotiating leverage of DSOs. Smaller groups, in particular, need to manage supplier relationships and contracts strategically.
  

• Potential vertical integration: With private equity stakes spanning suppliers and DSOs, opportunities may emerge for closer collaboration or integrated supply chain initiatives, reshaping traditional procurement and vendor relationships.

Looking ahead: This shift from small-scale clinic rollups to strategic realignments marks a new, sophisticated era of dental industry consolidation by PE. DSOs should closely monitor supplier dynamics, ensuring competitive pricing, supply chain stability, and leveraging improved technology and services. Proactively engaging suppliers and strategically adapting to these shifts will help DSOs navigate and thrive among the ups and downs of these giants.